Generic Industry Wants US FDA To Advance Research To Eliminate Need For Clinical BE Studies
Association For Accessible Medicines representatives say animal studies and in-silico trials could reduce the need for BE studies, but OGD director is not sure.
You may also be interested in...
During first half of fiscal 2018, US FDA only granted 16 of 31 pre-ANDA meeting requests, but said it was to ensure meetings were productive.
Despite in-vitro advances, FDA officials say more work is needed in refining alternative models before agency disbands its weight-of-evidence approach.